High prevalence of the CCR5Δ32 HIV-resistance mutation among Estonian HIV type 1-infected individuals

AIDS Research and Human Retroviruses

Volumn 23, Issue 2, 2007, Pages 193-197

  Adojaan, Maarja ^a   Mölder, Tarmo ^a   Männik, Andres ^a   Kivisild, Toomas ^a   Villems, Richard ^a   Krispin, Tõnu ^a   Ustav, Mart ^a,b  

^a UNIVERSITY OF TARTU   (Estonia)

^b FIT Biotech Oyj Plc Eesti   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ALLELE; ARTICLE; CONTROLLED STUDY; ESTONIA; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MUTANT; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VIRUS MUTATION; VIRUS RESISTANCE; ADOLESCENT; ADULT; AGED; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ESTONIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECEPTORS, CCR5; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33947224747     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0113     Document Type: Article

References (45)

1. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
2. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
3. Moore JP, Kitchen SG, Pugach P, and Zack JA: The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004;20:111-126.
4. Martinson JJ, Chapman NH, Rees DC, Liu YT, and Clegg JB: Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997;16:100-103.
5. O'Brien SJ and Moore JP: The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000;177:99-111.
6. Novembre J, Galvani AP, and Slatkin M: The geographic spread of the CCR5 delta32 HIV-resistance allele. PLoS Biol 2005;3:e339.
7. Galvani AP and Novembre J: The evolutionary history of the CCR5-delta32 HIV-resistance mutation. Microbes Infect 2005;7:302-309.
8. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
9. Venkatesan S, Petrovic A, Van Ryk DI, Locati M, Weissman D, and Murphy PM: Reduced cell surface expression of CCR5 in CCR5delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J Biol Chem 2002;277:2287-2301.
10. McNicholl JM, Smith DK, Qari SH, and Hodge T: Host genes and HIV: The role of the chemokine receptor gene CCR5 and its allele. Emerg Infect Dis 1997;3:261-271.
11. Voevodin A, Samilchuk E, and Dashti S: A survey for 32 nucleotide deletion in the CCR-5 chemokine receptor gene (deltaccr-5) conferring resistance to human immunodeficiency virus type 1 in different ethnic groups and in chimpanzees. J Med Virol 1998;55:147-151.
12. Reynes J, Portales P, Segondy M, et al.: CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000;181:927-932.
13. Visco-Comandini U, Hultgren C, Brostrom C, Birk M, Kim S, and Sallberg M: Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses. Clin Diagn Lab Immunol 1998;5:463-466.
14. Mulherin SA, O'Brien TR, Ioannidis JP, et al.: Effects of CCR5-delta32 and CCR2-64I alleles on HIV-1 disease progression: The protection varies with duration of infection. AIDS 2003;17:377-387.
15. Sullivan AD, Wigginton J, and Kirschner D: The coreceptor mutation CCR5delta32 influences the dynamics of HIV epidemics and is selected for by HIV. Proc Natl Acad Sci USA 2001;98:10214-10219.
16. Hladik F, Liu H, Speelmon E, et al.: Combined effect of CCR5delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005;79:11677-11684.
17. Agrawal L, Lu X, Qingwen J, et al.: Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol 2004;78:2277-2287.
18. Tang J, Shelton B, Makhatadze NJ, et al.: Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002;76:662-672.
19. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
20. Marmor M, Sheppard HW, Donnell D, et al.: Homozygous and heterozygous CCR5-delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001;27:472-481.
21. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
22. Alvarez V, Lopez-Larrea C, and Coto E: Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. Hum Genet 1998;102:483-486.
23. Huang Y, Paxton WA, Wolinsky SM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
24. Smith MW, Carrington M, Winkler C, et al.: CCR2 chemokine receptor and AIDS progression. Nat Med 1997;3:1052-1053.
25. Kalev I, Mikelsaar AV, Beckman L, Tasa G, and Parlist P: High frequency of the HIV-1 protective CCR5 delta32 deletion in native Estonians. Eur J Epidemiol 2000;16:1107-1109.
26. Matic S, Lazarus JV, and MC D: HIV/AIDS in Europe: Moving from Death Sentence to Chronic Disease Management. WHO Regional Office for Europe, Copenhagen, 2006.
27. Uuskula A, Kalikova A, Zilmer K, Tammai L, and DeHovitz J: The role of injection drug use in the emergence of human immunodeficiency virus infection in Estonia. Int J Infect Dis 2002;6:23-27.
28. Adojaan M, Kivisild T, Mannik A, et al.: Predominance of a rare type of HIV-1 in Estonia. J Acquir Immune Defic Syndr 2005;39:598-605.
29. Zetterberg V, Ustina V, Liitsola K, et al.: Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia. AIDS Res Hum Retroviruses 2004;20:1148-1156.
30. Briggs DR, Tuttle DL, Sleasman JW, and Goodenow MM: Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000;14:2937-2939.
31. Libert F, Cochaux P, Beckman G, et al.: The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998;7:399-406.
32. Najera R, Delgado E, Perez-Alvarez L, and Thomson MM: Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 2002;16(Suppl. 4):S3-16.
33. Gross KL, Porco TC, and Grant RM: HIV-1 superinfection and viral diversity. AIDS 2004;18:1513-1520.
34. Schinkel J, Langendam MW, Coutinho RA, Krol A, Brouwer M, and Schuitemaker H: No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis 1999;179:825-831.
35. Lukashov VV, Kuiken CL, Boer K, and Goudsmit J: HIV type 1 subtypes in The Netherlands circulating among women originating from AIDS-endemic regions. AIDS Res Hum Retroviruses 1996;12:951-953.
36. Lukashov VV and Goudsmit J: Founder virus population related to route of virus transmission: A determinant of intrahost human immunodeficiency virus type 1 evolution? J Virol 1997;71:2023-2030.
37. Op de Coul EL, Prins M, Cornelissen M, et al.: Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997. AIDS 2001;15:257-266.
38. Papa A, Papadimitriou E, Adwan G, et al.: HIV-1 co-receptor CCR5 and CCR2 mutations among Greeks. FEMS Immunol Med Microbiol 2000;28:87-89.
39. Meyer L, Magierowska M, Hubert JB, et al.: Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: Relationship with viral load. The SEROCO Study Group. AIDS 1997;11:F73-78.
40. Pollakis G, Abebe A, Kliphuis A, et al.: Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004;78:2841-2852.
41. Jensen MA, Li FS, van't Wout AB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77:13376-13388.
42. Tscherning C, Alaeus A, Fredriksson R, et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998;241:181-188.
43. Subbarao S, Vanichseni S, Hu DJ, et al.: Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand. AIDS Res Hum Retroviruses 2000;16:699-707.
44. Hu DJ, Buve A, Baggs J, van der Groen G, and Dondero TJ: What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS 1999;13:873-881.
45. Ciuffi A, Bleiber G, Munoz M, et al.: Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol 2004;78:10747-10754.